Medivir to present at the Redeye Growth Day
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Growth Day, today June 1, 2023. CEO Jens Lindberg will participate in an In Focus interview led by Redeye analyst Richard Ramanius, with focus on our proprietary project fostroxacitabine bralpamide (fostrox), at 13.35 CEST. The In Focus interview is live broadcasted and can be followed at the event page; https://www.redeye.se/events/871323/redeye-